Abstract
In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.
MeSH terms
-
Adult
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / pharmacology
-
Antipsychotic Agents / therapeutic use*
-
Bipolar Disorder / drug therapy*
-
Bipolar Disorder / physiopathology
-
Dibenzocycloheptenes
-
Drug Approval
-
Heterocyclic Compounds, 4 or More Rings / adverse effects
-
Heterocyclic Compounds, 4 or More Rings / pharmacology
-
Heterocyclic Compounds, 4 or More Rings / therapeutic use*
-
Humans
-
Randomized Controlled Trials as Topic
-
Schizophrenia / drug therapy*
-
Schizophrenia / physiopathology
-
United States
-
United States Food and Drug Administration
Substances
-
Antipsychotic Agents
-
Dibenzocycloheptenes
-
Heterocyclic Compounds, 4 or More Rings
-
asenapine